Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | PNLIP | P16233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733367 | 1.00 | LOX (0.36) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL1734201 | 1.00 | LOX (0.36) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL1735039 | 1.00 | LOX (0.36) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL1734021 | 1.00 | LOX (0.36) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL1733371 | 1.00 | LOX (0.36) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL6865791 | 0.98 | LOX (0.37) | LOXAOC3ALDH1A1HSD17B10LMNA | |
| SCHEMBL8081110 | 0.94 | TUBB1 (0.33) | LOXAOC3ALDH1A1 | |
| SCHEMBL6839095 | 0.89 | IDO1 (0.34) | LOXAOC3ALDH1A1TSHR | |
| SCHEMBL2984245 | 0.86 | MEN1 (0.38) | LMNAMAPK1TLR8 | |
| SCHEMBL2984114 | 0.86 | MEN1 (0.38) | LMNAMAPK1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2003130-B1 | NOVEL PYRIDINE DERIVATIVE HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | ARIGEN PHARMACEUTICALS INC (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011132683-A1 | BIS-CARBAZOLE DERIVATIVE, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME | 出光興産株式会社 (JP) | 2011-10-27 | — | — | WO | disclosed |
| US-20090143438-A1 | Novel Pyridine Derivative Having Anti-Helicobacter Pylori Activity | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-2003130-A9 | NOVEL PYRIDINE DERIVATIVE HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | aRigen Pharmaceuticals, Inc. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-2003130-A2 | NOVEL PYRIDINE DERIVATIVE HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | aRigen Pharmaceuticals, Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143438-A1 | Novel Pyridine Derivative Having Anti-Helicobacter Pylori Activity | MALT1, BCL6, PGC | LOX 2259/4885AOC3 3012/4885ALDH1A1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.